---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-23-000022"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:23:08.550056+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Recursion acquires Cyclica ($40M) & Valence ($47.5M); Q1 net loss $65.3M

## Summary
- Entered agreements to acquire Cyclica for $40M and Valence for $47.5M, payable in stock; expected Q2 2023 close.
- Q1 cash $473.1M; revenue $12.1M (up from $5.3M YoY) driven by Roche-Genentech collaboration.
- Net loss $65.3M vs $56.0M Q1 2022; R&D expenses rose to $46.7M on platform expansion.
- Phase 2 SYCAMORE trial (REC-994) in CCM: >80% enrolled; top-line data expected H2 2024.
- Phase 2/3 POPLAR trial (REC-2282) in NF2-mutated meningiomas; interim safety analysis expected 2024.

## SEC filing metadata
- accession: 0001601830-23-000022
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000022/0001601830-23-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000022/rxrx-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-23-000022
- JSON: https://secwatch.observer/filing/0001601830-23-000022.json
- Plain text: https://secwatch.observer/filing/0001601830-23-000022.txt

## Key facts
- Earnings Releases
  RECURSION PHARMACEUTICALS, INC. reported financial results for first quarter March 31, 2023.
  - Period: first quarter March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000022/0001601830-23-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.